Journal article
Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia
KF Bradstock, A Morley, K Byth, J Szer, I Prosser, P Cannell, I Irving, JF Seymour
Contemporary Clinical Trials Communications | ELSEVIER INC | Published : 2016
Abstract
An intensive induction regimen, consisting of idarubicin and high dose cytarabine, was assessed in 19 adult patients, median age 44 years, with newly diagnosed precursor-B acute lymphoblastic leukemia (ALL). Patients achieving a complete response (CR) were given an attenuated consolidation course. The primary endpoints were induction death rate and incidence of serious non-hematological toxicity. Grades 3-4 diarrhoea occurred in 47% of patients during induction. Two patients (11%) died during induction therapy, and 2 were withdrawn due to resistant disease or prolonged marrow hypoplasia. Fifteen patients achieved CR (79%), but levels of minimal residual disease (MRD) after induction were com..
View full abstractGrants
Funding Acknowledgements
We are grateful to Prof Lynda Campbell for interpretation of cytogenetic analyses on patients in this study, and to Dr Marnie Collins for statistical advice and assistance. We acknowledge the following physicians who contributed patients to the study: AnneMarie Watson, Townsville Hospital; Max Wolf, Miles Prince, Peter MacCallum Cancer Institute; Andrew Grigg, Royal Melbourne Hospital; David Gottlieb, Westmead Hospital; Robin Filshie, St Vincent's Hospital Melbourne. The study was partially supported by an unrestricted grant from Pharmacia Australia (now Pfizer Australia). The authors have no conflicts of interest to disclose.